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Myoepithelial cellsBreast cancer is the leading cause of cancer-relatedmortality for females worldwide [1]. Improving early screen-
ing strategies and understanding the events that lead to tumor initiation have led to demonstrable improvements
in clinical outcome. Our previous work revealed a variance in the tumorigenic capacity between different mam-
mary epithelial cell populations in anMMTV-ErbB2mouse model. In order to greater understand how different
mammary epithelial cells inﬂuence the tumorigenic capacity in ErbB2-induced breast cancer, we transplanted
different cell populations from pre-neoplastic MMTV-ErbB2 female mice into recipient mice for tumorigenic
study. We found that different mammary epithelial cells bear different tumorigenic potentials even when
induced by the same ErbB2 proto-oncogene. To understand the difference in tumors formed from different
epithelial cells, we performed gene expression proﬁling using these tumors (GSE64487). Several genes were
further validated using real-time reverse transcription polymerase chain reaction (RT-PCR). Here we provide
further details on the experimental methods and microarray analysis. This data provides a resource to further
understanding how different mammary cell populations can initiate ErbB2-driven tumors and the role of these
cell populations as putative tumor-initiating cells (TICs).
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).SpeciﬁcationsOrganism/cell
line/tissueMus musculusSex Female
Sequencer or
array typeIllumina Inﬁnium MouseWG-6 v2.0Data format Raw: Available in TXT ﬁle
Processed: Available in series_matrix.TXTExperimental
factorsMammary tumors derived from basal and luminal mammary
compartments.Experimental
featuresGene expression proﬁling inMMTV-ErbB2 tumors derived
from wild-type (WT) luminal progenitors (LP), myoepithelial
cells (Myo), and mammary stem cells (MSC). Additional
expression proﬁling for tumors derived from LP fromMMTV--
ErbB2/IkkαAA/AA (AA). The expression levels of selected genes
were conﬁrmed using RT-PCR.Consent N/A
Sample source
locationDepartment of Pathology, University of Iowa, Iowa City, IAniversity of Iowa/Carver College
2242, United States.
g).
. This is an open access article underDirect link to deposited data
Microarray: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=
GSE64487Experimental design, materials and methods
Tumor samples
Tumor samples were collected from paired primary cell grafts
from our previous work [2]. Brieﬂy, 5 × 104 sorted mammary epithe-
lial cells from MMTV-ErbB2 background were orthotopically trans-
planted into the #2 mammary fat pad of Rag1−/− female mice in a
pairwise fashion. The sorting scheme for individual cell populations
consisted of epithelial enrichment using Mammary Epithelial Cell
Enrichment Kit (Stemcell, Vancouver, BC, Canada), and magnetic
puriﬁcation against CD45-, CD31-, and Ter119-positve cells. Luminal
and basal cell populations were isolated using ﬂuorescence acti-
vated cell sorting (FACS) in the following scheme: CD24medCD49fhi
mammary stem cells (MSCs), CD24medCD49flo mature myoepithelialthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. Box plot of the quantile normalized expression level for the 12microarrays. The line
bisecting the boxplot is themean probe value. Samples appear in the order of seriesmatrix
ﬁle of GSE64487 dataset, the order of the original blinding of the RNA experiment.
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Fig. 2. A. Volcano plot displaying the gene expression fold change and P-value for LP WT ve
highlighted in red and fold-change≤ -1 and P-value≤ 0.05 (23 genes) in green. B. Heatmap of t
Samples are labeled according to the GSE64487 dataset.
120 N. Borcherding et al. / Genomics Data 4 (2015) 119–122cells (Myo), and CD24hiCD49floCD61+ luminal progenitors (LP). Tumor
growth was monitored over 3 months and tumor samples were
harvested before RNA extraction. Sample IDs in GSE64487 correspond
to Tumor_Cell Type_Allele_Mouse, i.e. Tumor_LP_WT_1. The ﬁnal
number on the ID corresponds to paired tumors derived from the
same mouse.RNA preparation
Total RNA was isolated from 20 mg of tumor samples that were
homogenized into RLT buffer (QIAGEN, Venlo, Limburg, Netherlands).
RNA was isolated using the RNeasy Plus mini kit (QIAGEN), according
to the manufacturer's instruction. RNA extracts were assessed for qual-
ity by Agilent 2100 Bioanalyzer, samples with A260/280 (2.0 ± 0.1),
A260/230 (2.0 ± 0.1), and RNA integrity number (RIN) ≥ 8.7 were
used for further experimentation [3]. Twelve tumor samples were
selected: 3 WT LP, 3 WT MSC, 3 WT Myo, and 3 MTV-ErbB2/IkkαAA/AA
(AA) LP.LP
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he 20most differentially expressed genes, asmeasured by absolute fold-change difference.
121N. Borcherding et al. / Genomics Data 4 (2015) 119–122Gene expression microarray
A total of 100 ng of RNA for each sample was submitted to the Iowa
Institute of Human Genetics Genomics Division for RNA sample prepa-
ration (cDNA synthesis and in vitro transcription). The Genomics
Division also performed the subsequent hybridization onto the
Illumina Mouse WG-6 v2.0 for 17 h at 58 °C. Chips were stained
with streptavidin-Cy3 (GE Healthcare, Piscataway, NJ) and scanned.
More detailed methodology of the Iowa Institute of Human Genetics
Genomics Division procedure for Illumina Mouse WG-6 v2.0 for this
microarray proﬁling has been described previously in supplemental
methods [4].
Microarray analysis
Beadchips were scanned with the Illumina iScan System and data
was collected using GenomeStudio software v2011.1. Microarray data
was quantile normalized and transformed into log2 expression by the
Iowa Institute of Human Genetics Bioinformatics Division (Fig. 1).
A total of 33,622 coding transcripts were analyzed using the
quantile-normalized values. Fold change was calculated by the average
log2 expression differences in the indicated group comparisons. The
volcano plots were generated in R with the use of Student's T test
and generic plot function. Genes highlighted in the volcano plots
had a P-value b 0.05 and an absolute value of the average log2 fold
change N 1 (red ≥ 1 log2 fold change and green ≤ -1). The 20 genesM
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Fig. 3.A.Volcano plot displaying the geneexpression fold change and P-value forMyoWTversus
and fold-change ≤−1 and P-value ≤ 0.05 (39 genes) in green. B. Heatmap of the 20 most dif
labeled according to the GSE64487 dataset.with the greatest fold change between the groups were further
displayed in heatmaps, generated in R using the gplots package [5].
Expression values were compared based on the tumor-initiating
cells (TICs) that gave rise to the tumors. Previously, we published the
comparison between LP- and MSC-derived tumors, ﬁnding that the
non-canonical Wnt5a was downregulated in MSC-derived tumors [4].
We also conducted comparisons between the tumors from LP WT
versus LP AA to investigate the transcriptional differences with the
inactivation of IKK-α (CHUK) in luminal progenitors (Fig. 2A, B).
We continued our transcriptional comparisons with the analysis of tu-
mors derived from Myo and MSC, two cell types of the basal compart-
ment that gave rise to ErbB2-driven tumors (Fig. 3A, B). Finally, as
another comparison between tumors derived from cells of the basal
versus luminal compartments,we compared the transcriptional proﬁles
of the Myo- and LP-derived tumors (Fig. 4A, B).
RT-PCR validation
For each isolated RNA sample, 1 μg was reverse-transcribed with
iSCript cDNA synthesis Kit (Bio-Rad, Hercules, CA). cDNA samples
were diluted (1:12) in nuclease-free water before RT-PCR was per-
formed using 96-Well Optical Reaction Plates (Applied Biosystems,
Life Technologies, Carlsbad, CA) and iTaq Universal SYBER Green
Supermix (Bio-Rad). A total of 15 μL of total reaction volume was used
in a ViiA 7 RT-PCR system (Applied Biosystems). Relative gene expres-
sion was quantiﬁed using the 2−ΔΔCT method [6], using Cyclophillin AM
SC
_W
T_
5
M
SC
_W
T_
1
M
SC
_W
T_
2
ld Change
1 2
MSCWT. Geneswith fold-change≥ 1 and P-value≤ 0.05 (30 genes) are highlighted in red
ferentially expressed genes, as measured by absolute fold-change difference. Samples are
M
yo
_W
T_
2
M
yo
_W
T_
5
M
yo
_W
T_
1
LP
_W
T_
1
LP
_W
T_
2
LP
_W
T_
5
Log2 Fold Change
-3 -2 -1 0 1 2 3
-
Lo
g1
0 
P-
va
lu
e
0
1
2
3
4A
Log2 Expression
B
4 6 8 10 12 14
Fig. 4.A. Volcano plot displaying the gene expression fold change and P-value for MyoWT versus LPWT. Genes with fold-change≥ 1 and P-value≤ 0.05 (14 genes) are highlighted in red
and fold-change≤ -1 and P-value≤ 0.05 (8 genes) in green. B. Heatmap of the 20most differentially expressed genes, asmeasured by absolute fold-change difference. Samples are labeled
according to the GSE64487 dataset.
122 N. Borcherding et al. / Genomics Data 4 (2015) 119–122(Ppia) (forward 5′-CAGTGCTCAGAGCTCGAAAGT-3′ and reverse 5′-
GTGTTCTTCGACATCACGGC-3′) as a housekeeping gene. A total of 24
genes were examined based on the differential expression of LP- versus
MSC-derived tumors. Results and primer sequences can be found in
previously published supplemental material [4].
Discussion
Herein we describe transcriptional proﬁling of breast tumors
derived from LP, MSC and Myo cell populations in the MMTV-ErbB2
background. We believe that this dataset could provide insights into
the characteristics of ErbB2-driven tumors derived from basal and lumi-
nal tumor-initiating cells, as both compartments are able to generate
tumors [2]. As MMTV-ErbB2-driven tumors are a murine model of the
aggressive HER2+molecular subtype of breast cancer, we believe that
this data may assist in further elucidation of the divergence in the 2
clinically deﬁned subclasses of HER2+ breast tumors: HER2-enriched
mRNA subclass and luminal-mRNA/HER2+ subclass [7].
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